Published: 2018-12-08

Articles

PHARMACEUTICAL EXPENDITURE COMPARED ACROSS COUNTRIES

C. van Mosseveld
Abstract 286 | PDF Downloads 167
PDF

TOXIC EPIDERMAL NECROLYSIS AND CLARITHROMYCIN

Nadia Khaldi, Alain Miras, Sophie Gromb
Abstract 281 | PDF Downloads 268
PDF

CLINICAL DATA GAP BETWEEN PHASE III CLINICAL TRIALS (PRE-MARKETING) AND PHASE IV (POST-MARKETING) STUDIES: EVALUATION OF ETANERCEPT IN RHEUMATOID ARTHRITIS

Pendar Farahani, Mitchell Levine, Kathryn Gaebel, Lehana Thabane
Abstract 759 | PDF Downloads 200
PDF

COMPLIANCE ASSESSMENT IN DRUG TRIALS: HAS THERE BEEN IMPROVEMENT IN TWO DECADES?

Shiva Jayaraman, Michael J Rieder, Doreen M Matsui
Abstract 295 | PDF Downloads 562
PDF

CARDIOVASCULAR COLLAPSE FROM LOW DOSE BUPIVACAINE

Marc E Levsky, Michael A Miller
Abstract 1339 | PDF Downloads 621
PDF

ARE BRAND-NAME AND GENERIC WARFARIN INTERCHANGEABLE? A SURVEY OF ONTARIO PATIENTS AND PHYSICIANS

Jennifer A Pereira, Anne M Holbrook, Lisa Dolovich Dolovich, Charles Goldsmith, , Lehana Thabane, James D Douketis, Mark Crowther, Shannon M Bates, Jeffrey S Ginsberg
Abstract 436 | PDF Downloads 208
PDF

CAN CANADA SUSTAIN PAEDIATRIC PHASE I TRIALS? A NATIONAL SURVEY OF CANCER RELAPSE IN CHILDREN

Loretta Lau Lau, Sylvain Baruchel
Abstract 228 | PDF Downloads 140
PDF

THE ROLE OF BUSPIRONE FOR THE TREATMENT OF CEREBELLAR ATAXIA IN AN OLDER INDIVIDUAL

Jayna M Holroyd-Leduc, Barbara A Liu, Brian E Mak I, Aleksandra Zecevic, Nathan Herrmann, Sandra E Black
Abstract 582 | PDF Downloads 162
PDF

CLINICAL TRIAL APPLICATIONS IN CANADA

Agnes V Klein, Anne M Tomalin
Abstract 390 | PDF Downloads 547
PDF